异动解读｜康诺亚-B盘中上涨7.1%，盈喜叠加创新药板块资金共振

行情直击07-20

7月20日，康诺亚-B盘中上涨7.1%，报87.45港元，成交额5078.37万港元。

消息面上，创新药板块今日集体活跃，多支头部公募密集触及港股创新药举牌线，板块资金共振明显。公司层面，近日发布正面盈利预告，预期上半年录得利润不低于人民币12亿元，上年同期亏损约7900万元，实现扭亏为盈。核心产品康悦达上半年收入超3.9亿元，同比增长超132%。此外，高盛于7月13日增持公司28.75万股，持股比例升至5.00%触及举牌线；TSLP/IL-13双抗CM512拟纳入突破性治疗品种，有望加速审评进程。多重利好叠加板块情绪催化，共同推动股价走强。

康诺亚生物医药科技有限公司专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品覆盖特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉等适应症。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1186797751?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-20 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186797751","market":"hk","top_or_hot":-1,"title":"异动解读｜康诺亚-B盘中上涨7.1%，盈喜叠加创新药板块资金共振","media":"行情直击","content":"<p><p>7月20日，康诺亚-B盘中上涨7.1%，报87.45港元，成交额5078.37万港元。</p><p>消息面上，创新药板块今日集体活跃，多支头部公募密集触及港股创新药举牌线，板块资金共振明显。公司层面，近日发布正面盈利预告，预期上半年录得利润不低于人民币12亿元，上年同期亏损约7900万元，实现扭亏为盈。核心产品康悦达上半年收入超3.9亿元，同比增长超132%。此外，高盛于7月13日增持公司28.75万股，持股比例升至5.00%触及举牌线；TSLP/IL-13双抗CM512拟纳入突破性治疗品种，有望加速审评进程。多重利好叠加板块情绪催化，共同推动股价走强。</p><p>康诺亚生物医药科技有限公司专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品覆盖特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉等适应症。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜康诺亚-B盘中上涨7.1%，盈喜叠加创新药板块资金共振</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜康诺亚-B盘中上涨7.1%，盈喜叠加创新药板块资金共振\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-20 10:35 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月20日，康诺亚-B盘中上涨7.1%，报87.45港元，成交额5078.37万港元。消息面上，创新药板块今日集体活跃，多支头部公募密集触及港股创新药举牌线，板块资金共振明显。公司层面，近日发布正面盈利预告，预期上半年录得利润不低于人民币12亿元，上年同期亏损约7900万元，实现扭亏为盈。核心产品康悦达上半年收入超3.9亿元，同比增长超132%。此外，高盛于7月13日增持公司28.75万股，持股...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1186797751","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186797751","pubTimestamp":1784514915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"7月20日，康诺亚-B盘中上涨7.1%，报87.45港元，成交额5078.37万港元。消息面上，创新药板块今日集体活跃，多支头部公募密集触及港股创新药举牌线，板块资金共振明显。核心产品康悦达上半年收入超3.9亿元，同比增长超132%。多重利好叠加板块情绪催化，共同推动股价走强。康诺亚生物医药科技有限公司专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品覆盖特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉等适应症。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"Interpretation of the change | Connoya-B rose 7.1% in the intraday session, and the earnings and benefits superimposed the funds of the innovative drug sector resonated","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"7月20日，康诺亚-B盘中上涨7.1%，报87.45港元，成交额5078.37万港元。消息面上，创新药板块今日集体活跃，多支头部公募密集触及港股创新药举牌线，板块资金共振明显。公司层面，近日发布正面盈利预告，预期上半年录得利润不低于人民币12亿元，上年同期亏损约7900万元，实现扭亏为盈。核心产品康悦达上半年收入超3.9亿元，同比增长超132%。此外，高盛于7月13日增持公司28.75万股，持股比例升至5.00%触及举牌线；TSLP/IL-13双抗CM512拟纳入突破性治疗品种，有望加速审评进程。多重利好叠加板块情绪催化，共同推动股价走强。康诺亚生物医药科技有限公司专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品覆盖特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉等适应症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186797751","isCrawlerRequest":true}